Share story
Science

First targeted therapy for Guillain-Barré syndrome nears approval by turning off rogue immune activity

New Scientist posted on X on Aug. 2 that a treatment turning off the part of the immune system that goes haywire in Guillain-Barré syndrome may be the first targeted therapy approved for the autoimmune condition. The post links to a New Scientist article about the potential approval. The treatment targets the rogue immune activity underlying the syndrome. No regulatory decision or timeline was disclosed in the post.
Sources
newscientist
Published by Tech & Business, a media brand covering technology and business. This story was sourced from newscientist and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital Infrastructure
Capital Infrastructure

Re:Build raises $2.1 billion to expand manufacturing capacity

Re:Build raised $2.1 billion to expand its capacity to manufacture hard tech products and launch industrial startups, TechCrunch reported. General Catalyst and JPMorganChase's Strategic Investment Group led the investment in the Massachusetts-based manufacturing accelerator.

TechCrunch
AI Capital
AI Capital

Lumaril raises $66 million for industrial AI software

Lumaril raised a $66 million Series A at a $400 million valuation, The Wall Street Journal reported. The company develops AI software that connects to manufacturers' existing control systems to optimize industrial production on factory floors.

Techmeme
Security Robotics
Security Robotics

VicOne reports 28 zero-day findings in software supporting robotics

VicOne says AI-assisted research identified 28 previously unknown vulnerabilities in less than two days across software supporting robotics, including projects developed or maintained by Google, NVIDIA and Meta. The findings span training, simulation and deployed operations.

The Robot Report